aTyr Pharma to Present at the LD Micro Main Event XVII in October
Rhea-AI Summary
aTyr Pharma, a clinical stage biotech company developing medicines from its tRNA synthetase platform, has announced its participation in the 17th Annual LD Micro Main Event. The event is scheduled for October 28-30, 2024, in Los Angeles, CA.
Dr. Sanjay S. Shukla, President and CEO of aTyr Pharma, will present a corporate overview on Tuesday, October 29, 2024, at 9:00am PDT at the Luxe Sunset Boulevard Hotel. The three-day event will feature approximately 150 companies presenting in half-hour increments and attending private meetings with investors.
Interested parties can view aTyr's presentation online and request meetings with management by contacting registration@ldmicro.com. This event provides an opportunity for aTyr Pharma to showcase its progress in developing first-in-class medicines to potential investors and industry professionals.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ATYR gained 0.45%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
San Diego, California--(Newsfile Corp. - October 14, 2024) - aTyr Pharma, Inc. (NASDAQ: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the 17th Annual LD Micro Main Event, which is scheduled to take place October 28 – 30, 2024, in Los Angeles, CA.
Details of the presentation appear below:
Conference: LD Micro Main Event XVII
Date: Tuesday, October 29, 2024
Time: 9:00am PDT
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA
The three-day event will feature around 150 companies, presenting in half-hour increments, and attending private meetings with investors. aTy's presentation will be available to view here. For more information and to request a meeting with management, please contact registration@ldmicro.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr's discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr's lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
About LD Micro
LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through the LD Micro Index and annual investor conferences, LD has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.
Contact:
Ashlee Dunston
Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226443
FAQ
When and where will aTyr Pharma (ATYR) present at the LD Micro Main Event XVII?
Who will be presenting the corporate overview for aTyr Pharma (ATYR) at the LD Micro Main Event?
How can investors view aTyr Pharma's (ATYR) presentation at the LD Micro Main Event?
How many companies are expected to present at the LD Micro Main Event XVII in October 2024?
How can investors request a meeting with aTyr Pharma (ATYR) management during the LD Micro Main Event?
